FDA Withdraws Approval of Eight Abbreviated New Drug Applications from Hospira, Inc. and Other Applicants

Summary

The US Food and Drug Administration (FDA) has withdrawn the approval of eight abbreviated new drug applications (ANDAs) from multiple applicants, including Hospira, Inc., following a request from the applicants to discontinue marketing the drug products.